Rocket Pharmaceuticals starts restructuring with workforce reduction of about 30%

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) began a restructuring on July 23, 2025 that includes a workforce reduction of about 30%. The company reported the plan in a Form 8-K under Item 2.05, which covers costs associated with exit or disposal activities. Martin Wilson, its general counsel and chief corporate officer, signed the filing.

What the plan does

Rocket calls the plan a strategic corporate reorganization and pipeline prioritization. Its board approved the plan unanimously on June 18, 2025, and the company began implementing it on July 23. The reduction in workforce, which the filing calls the RIF, is expected to be complete by August 8, 2025. The company began notifying affected employees on July 23.

Rocket says the RIF, together with other planned cost cuts, should reduce its 12-month operating expenses by nearly 25%. The stated aim is to extend operational runway into the second quarter of 2027.

The filing does not name the programs that will be cut or slowed. It refers only to "pipeline prioritization." The annual report for 2024, filed February 27, 2025, defines several conditions in its glossary, including Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency and Plakophilin-2 arrhythmogenic cardiomyopathy. The 8-K does not say which of its programs are affected.

The cost of the cuts

Rocket expects about $3.5 million in restructuring and restructuring-related charges in the second half of 2025. Most of that is severance and other termination benefits for about 80 employees. The estimate excludes non-cash charges tied to equity-based compensation.

The company also warns that it may incur expenses it has not yet planned for, and that its charges and savings are estimates that may differ materially. It says there is no assurance the plan or the RIF will have the intended effect on operating results and strategic decisions.

The scale of the charges is small next to the company's spending. The 10-K says operating activities used $209.7 million of cash in 2024, after a net loss of $258.7 million. In 2023, operating cash use was $194.9 million, against a net loss of $245.6 million.

The annual report says Rocket has no products approved for sale and has never generated product revenue. It puts the company's net cash proceeds from equity and convertible debt since inception at about $1.2 billion, through December 31, 2024. Its December 2024 offering and private placement raised $182.5 million net, from gross proceeds of about $194.7 million. The program-level expense table in the report lists Danon disease, plakophilin-2 cardiomyopathy, leukocyte adhesion deficiency-I, Fanconi anemia and pyruvate kinase deficiency among its programs.

What the filing leaves out

The 8-K does not give Rocket's cash balance, and it does not set out the assumptions behind the runway into the second quarter of 2027. The runway claim is a company projection that a reader cannot check from this filing.

The 8-K also does not say when the severance payments will be made beyond the second half of 2025, or whether the estimate will change once the RIF is complete.

The annual report's program table, which gives amounts in thousands of dollars, shows 2024 direct expenses of 23,677 for the Danon disease program RP-A501, down from 28,992 in 2023, and 17,749 for the Fanconi anemia program RP-L102, down from 25,276. Total research and development expense was 171,244 in 2024 against 186,342 in 2023. Martin Wilson, who signed the 8-K, is listed in the annual report as General Counsel, Chief Corporate Officer and Senior Vice President.

Report an error

Companies in this story

RCKTRocket Pharmaceuticals, Inc.NASDAQ · United StatesOpen the starter desk